Xylem Inc. (XYL) Balance Sheet

The asset growth is largely driven by the Evoqua acquisition, which added goodwill and intangibles, while the debt increase suggests acquisition financing. The balance sheet remains healthy, but the rising leverage warrants monitoring as integration progresses.

The debt increase appears tied to the Evoqua acquisition, but the absolute level remains manageable given the company's cash flow generation. The low D/E suggests ample refinancing flexibility, though the recent uptick indicates a shift toward more aggressive capital deployment.

The high goodwill concentration exposes the balance sheet to potential impairment if the Evoqua synergies fail to materialize. The stable PPE suggests limited organic investment, which may be appropriate for a service-oriented business but could limit long-term capacity expansion.

The steady accumulation of retained earnings reflects consistent profitability, but the surge in buybacks in 2026Q2 may signal a shift toward returning capital to shareholders. This could pressure equity growth if earnings growth slows, though the current equity base remains solid.

The current ratio remains above 1.5, indicating sufficient short-term liquidity, though cash levels are modest relative to total debt. The seasonal working capital swings noted in cash flow analysis suggest that liquidity can fluctuate, but the current position appears adequate for operational needs.